DURHAM, N.C. & SEATTLE--(

北卡罗来纳州达勒姆和西雅图--(

BUSINESS WIRE

商业热线

)--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation.

)--领先的表观基因组编辑公司Tune Therapeutics（Tune）今天宣布，由New Enterprise Associates、Yosemite、Regeneron Ventures和Hevolution Foundation牵头，完成超过1.75亿美元的融资。

“It is deeply gratifying to have seen this platform and company evolve so far,” said Tune Co-Founder Dr. Charles Gersbach, whose research at Duke University formed the basis for Tune’s TEMPO epi-editing platform. “Tune has already achieved a global landmark in the field, in the clinical application of epi-editing to a common and chronic disease.

Tune联合创始人查尔斯·格斯巴赫博士（CharlesGersbach）说：“很高兴看到这个平台和公司发展到目前为止。”他在杜克大学的研究为Tune的节奏epi编辑平台奠定了基础。“在epi编辑对常见和慢性疾病的临床应用方面，Tune已经在该领域取得了全球里程碑式的成就。

Thanks to the support of our investors, we anticipate the development of many more new epi-editing therapies in the years to come.”.

多亏了投资者的支持，我们预计在未来几年会开发更多新的epi编辑疗法。”。

The funding will accelerate the development of the company’s existing pipeline, currently anchored by Tune-401 – its clinical-stage epigenetic silencing drug for chronic Hepatitis B (HBV). It will also support the development of additional gene, cell, and regenerative therapy programs already underway at Tune, and to progress its broader mission of bringing the power and versatility of epigenetic therapies to bear on common and chronic diseases..

这笔资金将加速该公司现有管道的开发，该管道目前由Tune-401（其用于慢性乙型肝炎（HBV）的临床阶段表观遗传沉默药物）支撑。它还将支持Tune已经在进行的其他基因，细胞和再生治疗计划的开发，并推进其更广泛的使命，即将表观遗传疗法的力量和多功能性应用于常见和慢性疾病。。

“We are incredibly proud to see Tune progress successfully into the clinic,” said Reed Jobs, Founder and Investor at Yosemite. “The Yosemite team has been an enthusiastic backer of Tune from the beginning, as we feel that few technologies have the biological power of epigenetic medicine to transform disease outcomes for the better.

约塞米蒂的创始人和投资者里德·乔布斯（ReedJobs）表示：“我们非常骄傲地看到Tune在诊所取得了成功。”。“优胜美地团队从一开始就一直是Tune的热情支持者，因为我们认为很少有技术具有表观遗传学的生物力量来改善疾病的结果。

The range of potential applications and indications is .

潜在应用和适应症的范围是。

vast

巨大的

and will only continue to expand.”

而且只会继续扩大。”

“To date, modern medicine and pharmacology has done much to extend our lifespans, but far less for our active healthspans,” explains William Greene, Chief Investment Officer at Hevolution Foundation. “Chronic diseases of ageing are accelerating in incidence, prevalence, and severity, and current approaches are simply inadequate.

Hevolution基金会首席投资官威廉·格林（WilliamGreene）解释说：“迄今为止，现代医学和药理学在延长我们的寿命方面做了很多工作，但对我们的积极健康寿命却做得更少。”。“慢性衰老疾病的发病率、流行率和严重程度正在加速，目前的方法根本不够。

It is our belief that epigenetic editing may prove to be the transformative modality we need to enable a new era of regenerative medicine.”.

。

Since its founding in 2021, Tune has made impressive strides in the development and application of its novel and potentially transformative epigenome editing platform. At the 2023 ASGCT conference, Tune

自2021年成立以来，Tune在其新颖且具有潜在变革性的表观基因组编辑平台的开发和应用方面取得了令人瞩目的进步。在2023年ASGCT会议上

announced

已宣布

a global first in the field: the durable repression of a therapeutically relevant gene (PCSK9) in non-human primates using genetic tuning. This gene repression was accompanied by an enduring reduction of LDL cholesterol levels that is still ongoing almost 2 years after a single, transient delivery of the epi-silencing construct.

该领域的全球首创：使用基因调节在非人灵长类动物中持久抑制治疗相关基因（PCSK9）。这种基因抑制伴随着LDL胆固醇水平的持续降低，这种降低在epi沉默构建体单次瞬时递送后近2年仍在持续。

Later that year, the company .

那年晚些时候，该公司。

unveiled

揭幕

Tune-401, a first-in-class epigenetic silencer for chronic Hepatitis B, a condition that impacts over 250 million people, and is the leading cause of liver cancer worldwide.

Tune-401是治疗慢性乙型肝炎的一流表观遗传沉默剂，慢性乙型肝炎影响超过2.5亿人，是全球肝癌的主要原因。

In November of 2024, Tune announced it was moving to the clinical stage, having received approval to begin clinical trials in New Zealand, and subsequently in Hong Kong – supported by world-renowned hepatologists and Principal Investigators Dr. Ed Gane and Dr. Man-Fung Yuen, respectively. With its lead program now in the clinic, Tune is leveraging this momentum to enhance its platform capabilities and develop its other gene and cell therapy programs..

2024年11月，Tune宣布进入临床阶段，已获得批准在新西兰开始临床试验，随后在香港开始临床试验，分别得到世界著名肝病学家和主要研究人员Ed Gane博士和Man Fung Yuen博士的支持。Tune目前正在临床上开展领先项目，利用这一势头增强其平台能力，并开发其他基因和细胞治疗项目。。

“With this renewed support, we are well-positioned to advance our HBV clinical program, to invest in our platform, and to expand our pipeline,' said Akira Matsuno, Co-Founder, President and CFO of Tune Therapeutics. “We are grateful to all our investors for their deep confidence in our team and approach, backed by compelling data that continues to underscore the transformational potential of epi-editing as a therapeutic modality.'.

Tune Therapeutics联合创始人、总裁兼首席财务官松野明（Akira Matsuno）表示：“有了这种新的支持，我们完全有能力推进HBV临床计划，投资我们的平台，并扩大我们的渠道。我们感谢所有投资者对我们的团队和方法充满信心，并有令人信服的数据支持，这些数据继续强调epi编辑作为一种治疗方式的变革潜力。”。

About Tune Therapeutics

关于Tune Therapeutics

Armed with its powerful and innovative genetic tuning platform (TEMPO), Tune Therapeutics aims to bring gene, cell, and regenerative therapies into a new era of human medicine – expanding their range of application to common and chronic diseases.

凭借其强大而创新的基因调节平台（TEMPO），Tune Therapeutics旨在将基因，细胞和再生疗法带入人类医学的新时代-扩大其在常见和慢性疾病中的应用范围。

About Tune-401

关于Tune-401

Tune-401 is a first-in-class investigational product candidate for treating Hepatitis B (HBV) infection. Tune-401 utilizes the company’s versatile, modular TEMPO platform to epigenetically silence viral HBV intDNA and cccDNA necessary for sustained HBV infection. Lipid nanoparticle technology for Tune-401 has been provided by Acuitas Therapeutics Inc..

Tune-401是治疗乙型肝炎（HBV）感染的一流候选研究产品。Tune-401利用该公司的多功能模块化TEMPO平台表观遗传沉默持续HBV感染所需的病毒HBV intDNA和cccDNA。用于Tune-401的脂质纳米颗粒技术由Acuitas Therapeutics Inc.提供。。